99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization

Area of Science:

• Oncology
• Nuclear Medicine
• Surgical Pathology

Background:

• Sentinel lymph node biopsy is crucial for cancer staging.
• Traditional technetium-99m (99m)Tc-radiocolloids are standard for lymphatic mapping.
• Limitations exist with conventional radiocolloids regarding clearance and accumulation.

Purpose of the Study:

• To evaluate (99m)Tc-tilmanocept as a receptor-binding molecular imaging agent for lymphatic mapping.
• To compare the performance of (99m)Tc-tilmanocept against conventional radiocolloids in sentinel node localization.
• To highlight the advantages of (99m)Tc-tilmanocept for efficient resource use in oncologic procedures.

Main Methods:

• Utilized preoperative lymphatic mapping with intraoperative gamma-probe detection.
• Employed (99m)Tc-tilmanocept, an FDA-approved agent, for sentinel node localization.
• Assessed parameters such as injection site clearance, sentinel node extraction, and distal node accumulation.

Main Results:

• (99m)Tc-tilmanocept demonstrated rapid injection site clearance.
• High sentinel node extraction rates were observed with (99m)Tc-tilmanocept.
• Low accumulation in distal lymph nodes was a key characteristic of (99m)Tc-tilmanocept.

Conclusions:

• (99m)Tc-tilmanocept offers significant advantages over conventional (99m)Tc-radiocolloids for sentinel node localization.
• Its properties facilitate efficient resource utilization in cancer staging procedures.
• (99m)Tc-tilmanocept is a valuable tool for lymphatic mapping in various malignancies.